MARK2P6

Across TCGA pan-cancer cohorts, MARK2P6 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated MARK2P6 data layer.

The strongest signal is observed in thyroid carcinoma (THCA), where higher MARK2P6 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MARK2P6 expression acts as an unfavorable survival marker, although some lineages such as CHOL and COAD show a favorable association.

THCA, OV, and KIRC are the cancer types where MARK2P6 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	OS	Tertile	II,III,IV	0.897	0.991	<.001	63	view →
OV	OS	Quartile	All	0.579	0.714	<.001	48	view →
KIRC	DFS	Tertile	All	0.480	0.679	.003	46	view →
PCPG	OS	Tertile	All	0.809	0.986	<.001	42	view →
UCS	DFS	Tertile	IV	0.230	0.767	.009	36	view →
KICH	DFS	Tertile	All	0.424	0.888	.008	30	view →
MESO	OS	Tertile	II,III,IV	0.195	0.577	.023	27	view →
LUSC	OS	Tertile	IV	0.001	0.651	.025	18	view →
SKCM	DFS	Tertile	IV	0.036	0.433	<.001	15	view →
READ	DFS	Tertile	IV	0.295	0.661	.021	9	view →
CHOL	OS	Tertile	All	1.000	0.511	.048	6	view →
COAD	OS	Tertile	IV	1.000	0.489	.029	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

MARK2P6–THCA (OS)

Open the THCA breakdown →